1. Home
  2. ARVN vs PACB Comparison

ARVN vs PACB Comparison

Compare ARVN & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.27

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Logo Pacific Biosciences of California Inc.

PACB

Pacific Biosciences of California Inc.

HOLD

Current Price

$1.37

Market Cap

521.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARVN
PACB
Founded
2015
2000
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Laboratory Analytical Instruments
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
600.2M
521.8M
IPO Year
2018
2010

Fundamental Metrics

Financial Performance
Metric
ARVN
PACB
Price
$8.27
$1.37
Analyst Decision
Buy
Hold
Analyst Count
19
3
Target Price
$15.05
$1.67
AVG Volume (30 Days)
711.6K
5.6M
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
58.84
N/A
EPS
1.70
N/A
Revenue
$262,600,000.00
$93,468,000.00
Revenue This Year
N/A
$11.32
Revenue Next Year
N/A
$12.14
P/E Ratio
$4.89
N/A
Revenue Growth
N/A
3.04
52 Week Low
$6.97
$1.07
52 Week High
$14.22
$2.73

Technical Indicators

Market Signals
Indicator
ARVN
PACB
Relative Strength Index (RSI) 38.71 52.02
Support Level $7.90 $1.27
Resistance Level $8.40 $1.47
Average True Range (ATR) 0.32 0.07
MACD -0.13 0.01
Stochastic Oscillator 11.88 59.46

Price Performance

Historical Comparison
ARVN
PACB

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

About PACB Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.

Share on Social Networks: